{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:31:32Z","timestamp":1795131092935,"version":"4.10.3"},"reference-count":49,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,30]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>CDKN2A and TP53 deletions remain of bad prognostic value in younger MCL patients treated according to the current standard of care. CDKN2A and TP53 deletions have independent deleterious effects and should be considered for treatment decisions in addition to MIPI and Ki-67 index.<\/jats:p>","DOI":"10.1182\/blood-2015-02-628792","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T22:30:05Z","timestamp":1432852205000},"page":"604-611","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma"],"prefix":"10.1182","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-2343","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"first","affiliation":[{"name":"Department of Biological Hematology and Immunology, Assistance Publique H\u00f4pitaux de Paris (AP-HP), Groupe Hospitalier Mondor, Cr\u00e9teil, France;"},{"name":"Institut Mondor de Recherche Biom\u00e9dicale\u2013INSERM U955, Equipe 9, Henri Mondor Hospital, Cr\u00e9teil, France;"},{"name":"Universit\u00e9 Paris-Est, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospices Civils de Lyon, Lyon-1 University, Pierre Benite, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"INSERM U918, Institute for Research and Innovation in Biomedicine, Centre Henri Becquerel, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josette","family":"Briere","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Saint-Louis, AP-HP, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Lyon-1 University, Centre National de la Recherche Scientifique (CNRS), Unite Mixte de Recherche (UMR) 5239, Pierre Benite, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"CHU de Dijon, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"Centre Hospitalo-Universitaire Brabois, Nancy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Est, Cr\u00e9teil, France;"},{"name":"Lymphoid Malignancies Unit, GH Mondor, AP-HP, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, H\u00f4pital Saint-Louis, AP-HP, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Macintyre","sequence":"additional","affiliation":[{"name":"Biological Hematology, Necker Hospital, Paris Descartes, AP-HP, INSERM 1151, Institut Necker Enfants Malades, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[{"name":"Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, University Paris Descartes, CNRS, UMR 8147, Necker Hospital, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Munich, Munich, Germany;"},{"name":"Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111720170160300_B1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"2019111720170160300_B2","author":"Swerdlow"},{"issue":"11","key":"2019111720170160300_B3","first-page":"3909","article-title":"The Non-Hodgkin\u2019s Lymphoma Classification Project.","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2019111720170160300_B4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma.","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111720170160300_B5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.","volume":"87","author":"Vose","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111720170160300_B6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.seminhematol.2011.06.002","article-title":"Treatment of younger patients with mantle cell lymphoma.","volume":"48","author":"Harel","year":"2011","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111720170160300_B7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"2019111720170160300_B8","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111720170160300_B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte.","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2019111720170160300_B10","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.","volume":"23","author":"Fern\u00e0ndez","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111720170160300_B11","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma.","volume":"122","author":"Jares","year":"2012","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111720170160300_B12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas.","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"issue":"2","key":"2019111720170160300_B13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111720170160300_B14","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111720170160300_B15","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111720170160300_B16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2141.2008.07199.x","article-title":"Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis.","volume":"142","author":"Katzenberger","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111720170160300_B17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3324\/haematol.12330","article-title":"Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations.","volume":"93","author":"Sander","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111720170160300_B18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2009.07791.x","article-title":"Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.","volume":"146","author":"Jardin","year":"2009","journal-title":"Br J Haematol"},{"issue":"20","key":"2019111720170160300_B19","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma.","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"issue":"5","key":"2019111720170160300_B20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.semcancer.2011.09.007","article-title":"The complex landscape of genetic alterations in mantle cell lymphoma.","volume":"21","author":"Royo","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"2019111720170160300_B21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/gcc.20754","article-title":"Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.","volume":"49","author":"Espinet","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111720170160300_B22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2003-12-4175","article-title":"Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions.","volume":"104","author":"Kohlhammer","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111720170160300_B23","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.MP.0000037310.82136.99","article-title":"Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features.","volume":"15","author":"Hao","year":"2002","journal-title":"Mod Pathol"},{"issue":"9","key":"2019111720170160300_B24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00277-004-0879-2","article-title":"Coexistence of BCL1\/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome.","volume":"83","author":"Michaux","year":"2004","journal-title":"Ann Hematol"},{"issue":"4","key":"2019111720170160300_B25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900020406","article-title":"Growth fractions in malignant non-Hodgkin\u2019s lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67.","volume":"2","author":"Gerdes","year":"1984","journal-title":"Hematol Oncol"},{"issue":"1","key":"2019111720170160300_B26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111720170160300_B27","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111720170160300_B28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111720170160300_B29","first-page":"151","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net).","volume":"120","author":"Hermine","year":"2012","journal-title":"ASH Annu Mtg Abstr"},{"issue":"16","key":"2019111720170160300_B30","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111720170160300_B31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.seminhematol.2011.03.006","article-title":"Histopathology of mantle cell lymphoma.","volume":"48","author":"Klapper","year":"2011","journal-title":"Semin Hematol"},{"issue":"2","key":"2019111720170160300_B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network.","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"issue":"4","key":"2019111720170160300_B33","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111720170160300_B34","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"2019111720170160300_B35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ejhg.2011.60","article-title":"Multiplex ligation-depending probe amplification is not suitable for detection of low-grade mosaicism.","volume":"19","author":"van Veghel-Plandsoen","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"2019111720170160300_B36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2141.2008.07268.x","article-title":"Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia.","volume":"142","author":"Coll-Mulet","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111720170160300_B37","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111720170160300_B38","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111720170160300_B39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma\u2014a Nordic Lymphoma Group study.","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111720170160300_B40","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/sj.leu.2401901","article-title":"Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin\u2019s lymphoma.","volume":"14","author":"Gr\u00f8nbaek","year":"2000","journal-title":"Leukemia"},{"issue":"6","key":"2019111720170160300_B41","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)65071-7","article-title":"INK4a\/ARF locus alterations in human non-Hodgkin\u2019s lymphomas mainly occur in tumors with wild-type p53 gene.","volume":"156","author":"Pinyol","year":"2000","journal-title":"Am J Pathol"},{"issue":"4","key":"2019111720170160300_B42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3324\/haematol.12251","article-title":"Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.","volume":"93","author":"Jardin","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111720170160300_B43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111720170160300_B44","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL).","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111720170160300_B45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"29","key":"2019111720170160300_B46","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111720170160300_B47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haemato"},{"issue":"2","key":"2019111720170160300_B48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/leu.2013.249","article-title":"Combinatorial drug screening identifies synergistic co-targeting of Bruton\u2019s tyrosine kinase and the proteasome in mantle cell lymphoma.","volume":"28","author":"Axelrod","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"2019111720170160300_B49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V124.21.509.509","article-title":"Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199(GDC-0199), in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions.","volume":"124","author":"Portell","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/5\/604\/1391318\/604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/5\/604\/1391318\/604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T03:47:13Z","timestamp":1717904833000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/5\/604\/126423\/Highdose-cytarabine-does-not-overcome-the-adverse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,7,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-02-628792","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}